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CASE PRESENTATION
A 13-year-old Hispanic adolescent had presented at the age
of 4 years with an initial diagnosis of minimal change nephrotic
syndrome and growth failure. However, he was unresponsive to
therapeutic courses of steroids, cyclophosphamide, and cyclo-
sporine. Serial renal biopsies performed over 18 months even-
tually revealed focal segmental glomerulosclerosis (FSGS) with
a worsening chronicity index. Renal function gradually deterio-
rated and end-stage renal disease (ESRD) ensued. He had an
intractable nephrotic syndrome that warranted bilateral ne-
phrectomy prior to renal transplantation. At age 7, he received
a living related allograft, which was lost following delayed graft
function, multiple acute rejection episodes, and recurrence of
FSGS within 4 weeks after transplantation. Immediate plasma-
pheresis produced no remarkable clinical improvement.
After transplantation, the glomerular filtration rate (GFR)
deteriorated from 57 mL/min/1.73 m2 to 22 mL/min/1.73 m2
within 6 months to 6.5 mL/min/1.73 m2 by 12 months. Hemodi-
alysis (HD) was begun but was replaced with continuous cycling
peritoneal dialysis (CCPD) by 18 months post transplantation.
He developed a cytomegalovirus infection within 6 months
after the transplant surgery. Other complications included ure-
mic pericarditis, severe hypertension, septicemia, and a virus-
induced hemorrhagic anemia, necessitating 10 hospitalizations
per year in the first 2 years. Serial nutritional evaluations re-
vealed persistent growth failure with weight below the fifth, and
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height below the third, percentiles, respectively, for age and
gender (Figs. 1 and 2). Recombinant human growth hormone
(rhGH), given at an initial dose of 0.05 mg/kg/day at the age
of 8 years and increased to 0.06 mg/kg in 6 months, produced
a prepubertal growth spurt.
Pubertal growth advanced to Tanner stage II at age 10 and
stage III by age 12. The patient had improved tolerance for
physical exercise and greater involvement in sporting activities.
The dialysis adequacy, as measured by Kt/V at the onset of
CCPD, was 1.78 and improved to 2.25 after 6 months of rhGH
therapy. Before therapy with rhGH, he received 0.5 g/day of
calcitriol (1,25 dihdroxycholecalciferol); after treatment was initi-
ated, the dose was able to be reduced to 0.25 g/day to control
hyperparathyroidism. Currently 13 years of age, he has a bone
age of 12.5 years. His weight and height are in the 12.5 and
20 percentiles, respectively, for age and gender. In spite of his
chronic illness, he is a well-adjusted young adolescent with
exceptional motivation and above-average school achievement.
DISCUSSION
Dr. Frederick Kaskel (Director of Pediatric Nephrol-
ogy, Children’s Hospital at Montefiore, and Professor of
Pediatrics, Albert Einstein College of Medicine of Yeshiva
University, Bronx, New York): The normal kidney per-
forms an array of essential metabolic and physiologic
functions, including fluid and electrolyte regulation and
maintenance of acid-base balance, which are necessary
for promoting normal homeostasis and thereby ensuring
optimal cellular and organ function. The renal system is
involved in the production, processing, and secretion of
various hormonal substances, including 1,25 dihydroxy-
cholecalciferol, erythropoietin, and prostaglandins. This
system is of paramount importance in excretion of en-
dogenous nitrogen end products and toxic metabolites
of exogenous substances.
The metabolic consequences of poor renal function
are diverse and often multisystemic. The complexity of the
physiologic derangements in chronic renal disease (CRD)
and the nonspecificity of CRD’s clinical characteristics
are some of the reasons for its widespread late diagnosis.
Chronic renal disease is commonly under-recognized
and therefore under-treated in spite of the increasing
availability of therapeutic interventions that can slow its
progression and/or ameliorate an offending comorbidity.
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Fig. 1. Growth curve for case presentation.
This case highlights the impact of metabolic dysfunc-
tion in a growing child with CRD. In spite of the mile-
stones achieved in our care for pediatric patients with
CRD in the last few years, renal disease still constitutes a
significant source of biologic, physical, and psychosocial
burdens to this population. Indeed, virtually every cell
in the body is adversely affected by the unfavorable
metabolic milieu of chronic uremia. In this Forum I will
highlight some current concepts in growth failure as a
biophysical consequence of a uremic endocrinopathy
and nutritional alterations.
Growth failure
Growth failure is highly prevalent in children with
CRD, and it is a significant cause of morbidity and mor-
tality [1]. Pediatric patients with CRD, including renal
transplant recipients, have a significant height deficit [2].
At initiation of dialysis, 30% to 50% of patients have
heights below the third percentile for age; the final adult
height is compromised in approximately 50% of children
with prepubertal onset of renal disease [3]. The causes
of impaired linear growth might include protein energy
malnutrition, chronic metabolic acidosis, chronic ane-
mia, recurrent infection, and endocrinopathy [4].
Children normally go through three phases of somatic
growth and biologic maturation, each controlled pre-
dominantly by a different regulatory mechanism [4]. The
rapid growth in the first 2 years, influenced by favorable
nutritional and metabolic profiles, accounts for one-third
of the ultimate adult stature [4, 5]. The relatively stable
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Fig. 2. Growth velocity for case presentation. Abbreviations are: NS, onset of nephrotic syndrome; HD, hemodialysis; RTX, renal transplant;
GH, growth hormone.
growth in childhood is principally under hormonal con-
trol, including the growth hormone/insulin-like growth
factor-I (GH/IGF-I) axis and thyrotropin [4]. Twenty
percent of adult height is attained during puberty, which
is modulated both by growth and sex hormones [4–7].
The degree of growth retardation in CRD is often deter-
mined by the age of onset of renal disease. Infants with
congenital renal failure may suffer from intrauterine
growth retardation [4, 5]. Further loss in height occurs
during 0 to 3 months and 9 to 12 months; growth is relatively
preserved in mid-infancy. Early nutritional intervention
and prevention of metabolic deficits of renal failure can
preclude the development of severe stunting in the first
2 years of life [5]. Conservative treatment of predialysis
patients from birth to 3 years, that is, without the use of
rhGH, revealed a favorable growth rate, with height
velocity at 22.2, 10.9, and 7.6 cm per year, for each year,
respectively, all higher than the lower two standard devi-
ation scores (SDS) [5]. During childhood, patients with
CRD often grow at a rate equivalent to that achieved
by the end of the second year [6]. The loss of renal
function is the most important predictor of growth rate,
even though it accounted for only 10% to 15% of varia-
tion in growth [4]. In general, patients with GFR 25
mL/min/1.73 m2 maintain growth rate along the initial
trajectory, while those with GFR 25 mL/min/1.73 m2
Fig. 3. The GH–IGF axis. Abbreviations are:
ALS, acid labile subunit; GH, growth hor-
mone; GHBP, GH binding protein; GHRH,
GH releasing hormone; IGF, insulin-like
growth factor; IGFBP, IGF binding protein
(used with permission from Holt RIG: Fetal
programming of the growth hormone-insulin-
like growth factor axis. Trends Endocrinol
Metab 13(9):392-397, 2002).
Fig. 4. Hormones that control eating. Leptin
and insulin (lower portion of the figure) circu-
late in the blood at concentrations proportion-
ate to body-fat mass. They decrease appetite by
inhibiting neurons (center portion of the figure)
that produce the molecules neuropeptide Y
(NPY) and agouti-related peptide (AgRP),
while stimulating melanocortin-producing neu-
rons in the arcuate-nucleus region of the hypo-
thalamus, near the third ventricle of the brain.
NPY and AgRP stimulate eating, and melano-
cortins inhibit eating, via other neurons (top
portion of the figure). Activation of NPY/
AgRP-expressing neurons inhibits melano-
cortin-producing neurons. The gastric hormone
ghrelin stimulates appetite by activating the
NPY/AgRP-expressing neurons. Peptide YY
(3-36) (PYY3-36), released from the colon in-
hibits these neurons and thereby decreases
appetite for up to 12 hours. PYY3-36 works in
part through the autoinhibitory NPY receptor
Y2R (used with permission from Schwartz
MW, Morton GJ: Obesity: Keeping hunger at
bay. Nature 418:595–597, 2002).
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experience a loss in height of usually less than 0.2 SD/
year [6]. Height velocity prior to the growth spurt is re-
duced in children with CRD. The peak height velocity
of puberty is delayed by about 2.5 years, with a reduction
in its magnitude and total duration [8]. The pubertal
height gain is about 58% and 48% of that seen, respec-
tively, in late-maturing boys and girls without CRD; the
decline in mean height for boys is 2.9 SD and for girls,
–2.3 SD, respectively [8].
Chronic renal disease and its therapeutic modalities
can delay puberty by an average of 2 years [7]. In spite of
normal development of secondary sexual characteristics,
subnormal testicular growth is common and is associated
with germ cell deficiency, low sperm count, and perma-
nent loss of reproductive capacity in patients with a pre-
pubertal onset of renal failure [9]. Unlike adults, in these
patients, the sexual defects can fail to correct even after
renal transplantation [9].
Growth hormone is normally produced in abundant
quantity by the pituitary somatotroph cells [10] (Fig. 3).
It is basally secreted in a pulsatile manner, stimulated by
hypothalamic GH releasing hormone (GHRH), inhibited
by somatostatin, and is under the negative feedback of the
peripheral effectors GH and IGF-I [10]. Growth hormone
releasing hormone activates its receptor site, which in turn
induces G protein for stimulation of cyclic adenosine
monophosphate (cAMP) synthesis and a consequent
transcription of GH [11]. The two human GH genes are
located on chromosome 17 [11]. The hGH-N gene encodes
pituitary GH; its product undergoes a posttranslational
cleavage into two active GH with molecular weights of
21.5 kD and 20 kD [12]. The 21.5 kD form constitutes
approximately 90% of the circulating GH. The somato-
troph cells also possess receptors for GH releasing pep-
tide (GHRP), called GH secretagogue receptor (GHS-R).
The recent discovery of an endogenous secretagogue called
ghrelin [13] adds to the availability of several exogenous
(synthetic) GHRPs. Of the 5-somatostatin receptor sub-
types (SSTR1 to SSTR5), only SSTR2 and SSTR5 mediate
inhibition of GH secretion [14]. Growth hormone secre-
tion also is influenced by nutritional states: it is stimu-
lated by protein energy malnutrition, hypoglycemia, and
high protein meals but is inhibited by hyperglycemia [10].
Growth hormone in the circulation stimulates synthe-
sis of IGF-I in many tissues, most abundantly in the liver
[10]. Receptors for GH are glycoproteins, some of which
are solubilized to produce growth hormone binding pro-
tein (GHBP), a carrier protein that prolongs GH’s half-
life by several hours [12]. Growth hormone is the most
potent secretagogue for IGF-I, which mediates most, but
not all, of the action of GH. The IGF-Is are transported
in plasma bound to IGFBPs 1 to 6, but mostly to IGFBP-3,
which occurs in the circulation as a 150 kD ternary com-
plex bound to the IGF-I and its acid-labile subunit [15].
Only about 1% of plasma IGF-I occurs in the free bio-
active form. The IGFs have much higher affinities for
IGFBPs than do their receptors [16]. Furthermore, they
are protected from degradation by IGFBPs before their
release for receptor binding. The IGFBPs possibly re-
duce the bioactivity of IGFs by a competitive inhibition
of the tissue receptor. On the other hand, they also might
facilitate peripheral tissue action by a slow release of the
ligand, thereby preventing its premature degradation [16].
Insulin-like growth factor I also is synthesized in mes-
enchymal cells in virtually all human tissues in an auto-
crine (and/or paracrine) fashion, and some of it could
be secreted into the systemic circulation [10]. A small
single-chain peptide with a molecular weight of 7650 kD,
IGF-I belongs to the same family of genes as IGF-II and
proinsulin [17]. Its physiologic activities are mediated via
IGF-I receptors. The IGF-I receptors are hetero-tetra-
mers with 2 alpha and 2 beta subunits linked by disulfide
bridges [18]. These receptors are widely distributed in
different cell types, and they facilitate coordination of
sequential, proportionate, and symmetric body growth.
The IGF activates the receptor by binding to its extracel-
lular alpha subunit, which induces the transmembrane
beta-unit counterpart for an autoactivation of tyrosine ki-
nase [17], with a consequent phosphorylation of cytosolic
tyrosine residues and insulin receptor substrate (IRS-1
and -2). The intracellular signaling cascade causes down-
stream activation of the mitogen-activated protein 3
(MAP-3) kinase pathway, thus stimulating cellular growth.
Activation of IRS-1 also can stimulate the protein kinase
B pathway, which is important for protein synthesis, cell
motility, and inhibition of apoptosis [12].
Let’s compare the normal GH/IGF-I axis with that in
patients with CRD (Fig. 1). Growth hormone is secreted
from the pituary gland under the control of the hypothal-
amic hormones, somatostatin and GHRH, as well as the
mainly gastric ghrelin. GHRH and ghrelin bind to their
respective receptors in the pituitary and stimulate GH
secretion. Somatostatin inhibits GH secretion. GH circu-
lates, bound to GHBP, and acts through specific cell-
surface receptors. Most of the anabolic actions of GH are
mediated by IGF-I, which is produced in many different
tissues, with most circulating IGF-I being derived from
the liver. IGF-I acts through the IGF-I receptor by auto-
crine, paracrine, and classic endocrine mechanisms. IGF-I
is present in the circulation and extracellular space, al-
most entirely bound to IGFBPs that coordinate and reg-
ulate the biologic functions of the IGFs. Over 99% of
circulating IGF-I is bound in a ternary complex compris-
ing IGF-I, IGFBP-3, and an acid-labile subunit (ALS). The
major source of circulating IGFBPs and ALS is the liver.
IGF-I inhibits GHRH and GH secretion in a classic
negative feedback mechanism.
Growth hormone secretion by the hypothalamic-pitu-
itary tract is poorly regulated in patients with CRD. In
contrast to healthy individuals, in these patients, glucose
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infusion increases secretion of GH rather than inhibiting
it [18]. Children with CRD can have increased (pulsatile)
release of GH, the mechanism for which is unknown
[18]. In addition, these patients have reduced renal clear-
ance of GH that correlates with the loss of GFR. In spite
of an elevated serum GH level, the serum IGF-I concen-
tration does not increase because its hepatic synthesis is
reduced [10]. Furthermore, the bioavailability of IGF-I
is compromised because the levels of IGFBP-1, -2, -4,
and -6 rise [9]. As a result of an increased proteolysis of
IGFBP-3, less IGF-I circulates as a ternary complex (150
kD) [19]. Conversely, IGFBP-3 (29 kD) fragments in-
crease, and these have less affinity for IGF-I. Conse-
quently, effective delivery of IGF-I to its sites of action
is reduced [17–19]. There also can be end organ resis-
tance to GH and IGF-I in chronic uremia. A study of
uremic rats showed a reduction in GH receptor density
in tibial growth plate [20] and low levels of mRNA for
hepatic GH receptor [21]. Furthermore, chronic uremia
is characterized by a defect in postreceptor signal trans-
duction; tyrosine phosphorylation of JAK2, STAT5, and
STAT3 is impaired because of overexpression of sup-
pressor of cytokine signaling-2 (SOCS-2) proteins [21].
Body weight and its composition are under strict con-
trol by the hypothalamic system, which maintains a con-
sistent “set point” by receiving feedback from peripheral
effectors [22] that can include leptin and ghrelin (Fig. 4).
Ghrelin, an acylated peptide with a molecular weight
of 3300 kD, is a recently discovered endogenous GH
secretagogue isolated from the stomach, hypothalamus,
and systemic circulation of humans and rats [13, 23]. It
is produced by the gastric Gr-cells, which are morpholog-
ically similar to the pancreatic alpha cells, and in lesser
amount by the arcuate neurons of the hypothalamus. It
is more potent than GHRH, stimulating GH release in a
dose-dependent manner [24]. In addition to GH release,
secretion of adrenocorticoid hormone (ACTH) and pro-
lactin (PRL) also is increased, but ghrelin has no effect on
luteinizing hormone (LH), follicle-stimulating hormone
(FSH), and thyroid-stimulating hormone (TSH) [24].
The range of its activity in humans is currently being
defined, although recent studies suggest a role in the
regulation of feeding behavior and body composition.
A randomized, double-blind, crossover trial in humans
showed an increase in visual analog scores for appetite,
total food intake, and energy consumption in study sub-
jects [25]. However, unlike in rats, no effect on gastric
emptying was seen, probably because of a relatively
lower dose used in the human subjects. The mechanism
for ghrelin’s peripheral action could be inhibition of fatty
acid oxidation and up-regulation of glycolysis, as sug-
gested by an increase in respiratory quotient following
systemic administration in rodents [23].
Evidence indicates that plasma ghrelin is generally
increased by a negative energy balance but down-regu-
lated by a positive energy balance; plasma ghrelin corre-
lates negatively with body mass index [26]. In addition,
the plasma ghrelin concentration is higher in patients with
anorexia nervosa but lower in obese subjects. Plasma
ghrelin level falls following either oral or intravenous
glucose administration [26]. Ghrelin mRNA is up-regu-
lated in the stomachs of rodents after fasting and is re-
stored to normal value after refeeding, although the in-
tracellular signal for its release is unknown. The diurnal
variation of ghrelin secretion consists of a preprandial
increase and a decrease in level after feeding, followed
by a nighttime peak at approximately 2:00 a.m. [26].
Ghrelin therefore might play a role in the physiologic
initiation of food intake [23], and alteration of its func-
tion could contribute to poor dietary intake and nutri-
tional insufficiency in patients with CRD.
Leptin is a protein product of the obesity gene (ob)
[27]. It is secreted by adipocytes, transported in plasma
by leptin-binding protein, and released into the central
nervous system. It decreases synthesis of anorexigenic
neuropeptide Y (NPY) by activation of Jak/STAT sig-
naling in agouti-related-protein (hypothalamic) neurons
[28]. A highly potent anorectic, NPY promotes energy
expenditure and weight loss. Whereas ob/ob mice have
genetic traits of leptin deficiency, db/db mice have leptin
receptor insensitivity with a resultant hyperleptinemia
[29]. Both models are characterized by gross obesity,
high food intake, insulin hyporesponsiveness, and reduced
energy expenditure.
No substantiated data are available on the biologic
role of leptin in CRD. Studies are mostly of cross-sec-
tional design. However, given the role of leptin in the
regulation of nutrition and body weight in health, leptin
might play a significant role in the anorexia and weight
loss of CRD. Serum leptin, mostly the free bioactive
form, is elevated in many patients with CRD [30]. The
mechanism for its retention is unclear; data on renal clear-
ance and/or metabolism of leptin are conflicting. How-
ever, given its molecular weight of 16,000 kD [27], renal
filtration would be expected, and poor renal clearance
with low GFR has been documented [30]. Furthermore,
interleukin-1 (IL-1) and tumor necrosis factor- (TNF-)
cytokines, both commonly elevated in CRD patients, can
induce leptin release from adipocytes [31]. But leptin’s
relationship with C-reactive proteins is poorly defined;
the results of studies vary from a positive [32] to a nega-
tive [33] correlation. Intradialysis parenteral nutrition
elevates plasma GH and insulin, which synergistically
stimulate the release of leptin from peripheral tissues;
this effect might be simulated by free IGF-I [34].
Unlike the appetite-stimulating peptide ghrelin, leptin
might play a negative regulatory role in food intake in
the body’s attempt to maintain an ideal nutritional status
and body composition. Leptin limits excessive weight
gain, especially body fat mass [35]. Thus, a negative cor-
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relation exists between leptin and serum albumin or lean
body mass [35]. On the other hand, an elevated serum
leptin level also is found in obese patients [32], and it
correlates with the body fat mass, presumably an attempt
to down-regulate food intake. That a prospective study
discerned a direct correlation between serum leptin/fat
body mass ratio with weight loss in HD patients suggests
a role for leptin in the loss of lean body mass [36].
Altered nutrition in CRD
Protein energy malnutrition is strongly associated with
high morbidity and mortality rates in dialysis patients
[37]. It is seen in 44% of patients at the initiation of
dialysis [38]. In addition, a direct correlation exists be-
tween a progressive decline in GFR and deteriorating
nutritional indices in most patients with CRD [38].
Chronic renal disease might be associated with retention
of a yet-to-be identified “anorectic peptide,” probably a
middle molecule toxin [38] and/or leptin. Although data
on basal energy expenditure (BEE) seem to conflict
(they are mostly cross-sectional in design), there is a
tendency for an elevated BEE in patients with advanced
CRD but suppression of BEE in patients with chronic
renal insufficiency [39]. Thus a direct negative correla-
tion exists between resting metabolic rate and GFR as
measured by creatinine clearance [39].
In general, dietary energy intake is lower in patients
with CRD because of a spontaneous or therapeutic re-
duction in protein intake and low calorie consumption.
The decreased BEE in early CRD might represent an
adaptive response to poor dietary energy consumption;
the low protein intake in predialysis patients often causes
reduced oxidation of amino acids, thus enhancing effi-
cient utilization [40]. Furthermore, as I said earlier, cellu-
lar metabolism is down-regulated in uremic states, with
tendencies for reduced protein synthesis but increased
degradation. In addition, patients with CRD have an
adaptive low thyroid state, and correction often acceler-
ates negative nitrogen balance and protein degradation
[41]. These patients also have impaired peripheral con-
version of T4 to T3 and decreased binding of T4 to
thyroid-binding protein (TBG), but TSH level is within
normal limits [41].
Early CRD brings a loss of lean body mass but a
preservation of fat mass [42], probably due to an interplay
of metabolic processes with lipogenic influences from
GH/IGF-I [10, 12] and also possibly from ghrelin [24–26].
On the other hand, the loss of skeletal muscle mass might
result from uremia per se, micro-inflammation, meta-
bolic acidosis, nutritional insufficiency [38, 43, 44], and
possibly hyperleptinemia [36]. However, at the later stage
of CRD, these adaptive responses can be overwhelmed
by hypercatabolic factors (for example, infection, oxida-
tive stress, cytokines, dialysis) with a consequent loss of
lean and fat body masses [45]. An important factor in
the regulation of body composition is the metabolic con-
sequence of uncoupling proteins (UCP) [46]. Upon acti-
vation these proteins, exclusively expressed in brown
adipose tissue, uncouple mitochondrial oxidative phos-
phorylation, which possibly accounts for about one-fifth
of BEE. Tumor necrosis factor might promote up-regula-
tion of UCP-2 and UCP-3 genes in skeletal muscles of
uremic rats [31]. Although the role of UCP polymor-
phism as a determinant of adverse nutritional outcome
in CRD is yet to be elucidated, it could explain the vari-
ability in biologic adaptation to metabolic stresses (includ-
ing nutritional deficit) in patients with renal disease [47].
The combined effect of metabolic acidosis, chronic
inflammation, and uremia likely increases protein degra-
dation by activating the ubiquitin-proteasome pathway
(UPP) [43], inducing branched-chain ketoacid dehydro-
genase [44], increasing insulin resistance [16], and im-
pairing functions of GH/IGF-I [15, 19]. In addition, meta-
bolic acidosis is a potent inhibitor of hepatic albumin
synthesis [43]. Furthermore, the catabolic effect of meta-
bolic acidosis is increased multiple-fold by glucocorticoid
released in response to an intense inflammatory state
[43, 44]. Conversely, in the absence of steroids, UPP
often is suppressed by an activated nuclear factor-B
(NF-B), thereby limiting protein degradation [43, 44].
In conclusion, in spite of years of research, the bio-
molecular characteristics of “uremic toxins” remain poorly
understood. However, there is little doubt about the pro-
found adverse metabolic effects of uremia on biocellular
activities. The multisystemic dimension of its impact un-
derlies the need for early and aggressive therapy, includ-
ing renal replacement, optimal nutrition, and rhGH in
the pediatric population. The efficacy of available modal-
ities of care can be enhanced by taking advantage of
our current understanding of the pathophysiology of the
disease. Thus, a need exists for combined rhGH therapy,
which can include GHrP/ghrelin, IGF-I, and GH to
mimic the physiologic state. We must intensify our efforts
to reduce the “uremic load” with a more efficient and
perhaps more frequent dialysis. The close interaction
among protein energy malnutrition, microinflammation,
and cardiovascular diseases necessitates a search for a
more effective therapy to break this vicious cycle. Further-
more, studies are needed to define the biologic roles and
therapeutic potentials of leptin and ghrelin in CRD. To
realize these goals, concerted efforts by the nephrology
community, primary care physicians, and the public are
needed to improve early diagnosis of renal diseases. The
need exists for a change in the public’s health behavior
concerning CRD. The public must be motivated to seek
routine medical evaluation and screening, screening for
renal disease for those with a family history, and prompt
follow-up when required. It has been estimated that a
substantial proportion of the American populace has
undiagnosed chronic renal insufficiency.
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QUESTIONS AND ANSWERS
Dr. John T. Harrington (Division of Nephrology,
Tufts-New England Medical Center, Boston, Massachu-
setts): In the boy you presented today, GH wasn’t used
until 1 year after renal transplanation. Can it be used
sooner? Is the delay in administering GH based on the
premise of “do no harm?” Or is it because adverse clini-
cal effects have been seen post transplantation? Have
experimental animals received GH from day 1 post trans-
plant?
Dr. Kaskel: It appears that we withhold GH not only
because of concerns about rejection, but also because of
concern for renal function. Experimental studies have
shown that GH in transgenic animals reduces renal func-
tion [48]; this adverse effect was not seen in animals trans-
genic for IGF-I. That might be one of the reasons why
GH is not being used right away after transplantation.
Dr. Harrington: If my recollection is correct, some
children with partial lipodystrophy have progressive re-
nal failure. What do we know about the peculiarities of
growth failure, ghrelins, or leptin in these patients with
partial lipodystrophy? Dr. Chesney, can you enlighten us?
Dr. Russell W. Chesney (Professor and Chairman,
Le Bonheur Children’s Medical Center and University of
Tennessee, Memphis, Tennessee): The partial lipodystro-
phies are a heterogeneous group of disorders that include
loss of upper body subcutaneous adipose tissue, insulin
resistance, hyperlipidemia, and diabetes mellitus [49].
The typical autosomal-dominant form, which has no spe-
cific renal involvement, is associated with mutations in
the nuclear laminin A, known as the familial partial lipo-
dystrophy of Dunnigan (FPLD). Laminins are necessary
for nuclear functioning, including bidirectional nuclear
membrane transcription factors. Plasma leptins are re-
duced mainly in complete lipodystrophy in which lipo-
atrophy is not confined to the upper body. In mouse
models of complete lipodystrophy, leptin administration
can reverse diabetes and insulin resistance.
When partial lipodystropy is associated with progres-
sive renal disease, the renal histologic finding is mesangio-
capillary glomerulonephritis (MPGN) type II [50]. In par-
tial lipodystrophy with type II MPGN, patients have a
serum immunoglobulin termed complement 3 nephritic
factor (C3NeF) [51]. C3NeF is an autoantibody that binds
factor H, which regulates the overwhelming activation of
complement. In its bound form, factor H cannot prevent
complement depletion and the development of membra-
noproliferative glomerulonephritis (MPGN) [52]. Patients
with homozygous complement factor D deficiency also
can show partial lipodystrophy with MPGN type II [52].
Dr. Sushil Sagar (Albert Einstein College of Medi-
cine, Bronx, New York): Dr. Kaskel, you mentioned that
IGFBPs are elevated in CRD. Do we understand what
makes the levels increase?
Dr. Kaskel: Experimental data in several animal mod-
els of renal failure show that the elevated IGFBPs might
be related to at least two factors. First, there is increased
liver mRNA for some binding proteins in spite of re-
duced hepatic GH receptors [53]. Second, there is a
buildup of the binding proteins because of poor renal
clearance [54]. In other words, there is dysregulation of
both synthesis and clearance.
Dr. Michael Goligorsky (Director, Division of Ne-
phrology, New York Medical College, New York, New
York): Since growth retardation is not uniformly ob-
served in all children with CRD, I think it is possible to
learn a lot from the group that does not experience
growth failure. Has there ever been a side-to-side com-
parison of the metabolic profiles of these two groups?
Dr. Kaskel: That is a very important question. Some
of us have attempted to examine this question in a
multicenter study funded by Genentech. I was working
with Dr. Johnson and other members of our collabora-
tive group looking at the GH/IGF-I axis and body com-
position of these two groups of patients who were on
dialysis. Unfortunately, we weren’t able to get that study
completed. Valerie, do you have anything to add?
Dr. Valerie Johnson (Director, Division of Pediatric
Nephrology, New York Weill Medical College of Cornell
University, New York, New York): Body composition
data from some European studies show no difference
between these groups matched for age and gender [55].
But nobody has looked at these groups carefully to deter-
mine why they behave differently metabolically.
Dr. Fatai Bamgbola (NIH Clinical Research Fellow in
Pediatric Nephrology, Children’s Hospital at Montefiore,
Bronx, New York): This phenomenon might be due to
genetic differences among these patients. In Pima Indians,
for instance, homozygous deletion of the UCP-2 gene
contributes to a high prevalence of obesity [56]. As
pointed out by Dr. Kaskel, UCP-2 and UCP-3 are re-
cently discovered genes, predominantly found in brown
adipose tissue, which upon activation can lead to uncou-
pling of mitochondrial oxidative phosphorylation and
therefore to increased basal energy expenditure. There
is a well-designed study in patients on peritoneal dialysis,
a unique population because they are constantly exposed
to a highly glycemic milieu, in which increased adiposity
was demonstrated in the subgroup of subjects with UCP-2
homozygous gene deletion [47]. In addition, I believe
the differences in biologic adaptation to metabolic stress
also can be related to factors that might include induction
of the UCP genes by TNF- and differential activation
of the ubiquitin-proteasome system, a major protein deg-
radation pathway.
Dr. Chesney: Some recent studies have looked at poly-
morphisms of promoter regions for TNF- and trans-
forming growth factor- (TGF-). Patients with TNF-
gene defects have more serious disease in certain clin-
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ical conditions, such as Kawasaki disease [57]. This gene
defect is also seen in adults with acute respiratory dis-
tress syndrome, severe pneumonia, and sepsis [58]. We
need to look at cytokine gene polymorphisms in patients
with CRD.
Dr. Goligorsky: Do children with CRD have hyper-
homocysteinemia as adults do?
Dr. Chesney: Human studies have shown that adults
with hyperhomocysteinemia are more likely to develop
cardiovascular disease [59]. However, in patients with
cardiovascular disease, instead of having hyperhomocys-
teinemia, they have low plasma homocysteine levels.
This discrepancy is probably related to the malnutrition
associated with cardiovascular disease.
Dr. Leigh Ettinger (Fellow in Pediatric Nephrology,
Children’s Hospital at Montefiore, Bronx, New York): Do
you know of any study on the effect of growth hormone
therapy on cardiovascular morbidity and mortality in
patients with CRD?
Dr. Bamgbola: One study in adult patients with con-
gestive heart failure showed that administration of GH
improved cardiovascular function [60].
Dr. Kaskel: Let me add that there is scanty evidence
concerning GH’s cardiovascular effects in children, and
this issue needs to be investigated.
Dr. Sandra Blethen (Head of Endocrine Medicine,
Genentech, Inc., San Francisco, California): Certainly in
GH-deficient adults, particularly women, GH therapy
improves clinical outcomes. Also, a recent trial by Dr.
Kaufman at the Los Angeles Children’s Hospital involv-
ing GH-deficient children showed that the subjects who
did not receive GH had a very high homocysteine level
(abstract; Krantz J et al, Pediatr Res 49:609, 2001).
Dr. Paul Saenger (Director of Pediatric Endocrinol-
ogy, Children’s Hospital at Montefiore, Bronx, New York):
Dr. Ettinger, your question addresses a possible adverse
cardiovascular effect of GH because it is a growth pro-
moter. I don’t think we have any information on children
with GH deficiency. There are data on children with
Turner’s syndrome and intrauterine growth retardation
who were treated with GH, using the same doses as in
children with renal failure [61]. There were no adverse
effects on cardiovascular function as measured by cardiac
ultrasound in these patients.
Dr. Manju Chandra (Chief of Pediatric Nephrology,
North Shore University Hospital, Long Island, New York):
In infants with congenital renal malformation and renal
failure, what is the earliest time to start GH therapy?
Dr. Kaskel: We usually don’t start GH until the infant
reaches 1 year of age. Dr. Blethen, would you like to
comment?
Dr. Blethen: I think the ideal approach is to provide
basic nutrition and achieve metabolic correction. Dr.
Fine showed that children less than 2 years of age do
respond to GH [61]. The main question is, once there is
evidence of growth failure, and you’ve done the best you
can with all the other weapons that you have, is that
the best time to start GH? In our experience with GH-
deficient children, the earlier you start, the better the
outcome in maximizing their growth.
Dr. Bamgbola: I’d like to mention the importance of
supportive therapy. A German study of children less than
3 years of age with congenital renal failure who were
managed strictly on a conservative regimen (in a tertiary
health care institution, whereby adequate control of nu-
trition and metabolic profiles was provided) found that
the children sustained adequate growth in weight and
stature, at least in the first 2 years of life [5]. It is therefore
of paramount importance to provide excellent support-
ive care to maximize children’s growth before the age
of 2. Thereafter, optimal growth is equally dependent
on the rate of GFR loss and endocrinologic factors, in-
cluding GH and thyrotropin. During this latter phase
of somatic development, adjunct GH therapy is often
necessary.
Dr. Harrington: One of the newer nutritional issues
in adult patients is carnitine deficiency. A whole industry
is marketing carnitine lotion and pills to the populace
to enhance muscle strength and development. Are there
studies in children with CRD?
Dr. Kaskel: We screened 20 children on HD, and at
least 17 of them had carnitine deficiency. Studies in Europe
have shown carnitine deficiency in children on dialysis
[62]. Dr. Schreiber from Michigan, an expert on this
topic, believes that carnitine deficiency affects virtually
every system in the body [63]. This is a wide-open field,
and we are about to study this problem in a more con-
trolled fashion.
Dr. Goligorsky: In treating children with GH, do we
use a standard dose, or is the dose titrated according
to certain parameters such as IGF-I level or something
else?
Dr. Kaskel: We use a starting dose of 0.05 mg/kg/day
at the onset and increase the dose as needed over time.
Dr. Blethen: In clinical trials, you have to keep the
protocol simple, so children are often treated with a fixed
dose of GH. There is certainly a desire in the medical
community to maintain the IGF-I level above average
values, but not excessively so. The problem with the
measurement of free IGF-I is that not everyone agrees
on how to do it. There is a commercially available kit,
but some people think it is not the best tool. I don’t
believe there are sufficient solid data out there.
Dr. Johnson: Growth rate drops after the second to
third year of GH therapy. Do you think that the IGF-I
level has something to do with it?
Dr. Blethen: The so-called “waning effect of GH ther-
apy” has been recognized for years. We still don’t under-
stand it. I believe your observation is correct, because
you can overcome the waning effect in some instances
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by bumping up the dose of the GH. Many years ago,
Dr. Gertner did a study when GH was provided by the
government and many were given a fixed-dose regimen
[64]. He persuaded one of the manufacturers to give him
extra supplies, and he found that he could increase the
growth rate by increasing the dose. I know he didn’t
look at IGF-I in that study, but even if he had, the
data would have been difficult to interpret given the
limitations of the IGF assays available then.
Dr. Chesney: I have one comment about GHBP in
children with CRD. Unless one has a very precise anti-
body that does not cross-react with other peptides, the
presence of many peptide compounds in uremic plasma
confounds their measurement. This is certainly true with
respect to GH and its binding proteins. And it accounts
for the difficulty in measuring GHBP in uremic children
and comparing it with measurements in other patients
such as those with Turner’s syndrome or partial lipodys-
trophy.
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